News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
282,252 Results
Type
Article (14688)
Company Profile (63)
Press Release (267501)
Multimedia
Podcasts (77)
Webinars (13)
Section
Business (101428)
Career Advice (468)
Deals (15510)
Drug Delivery (99)
Drug Development (36970)
Employer Resources (51)
FDA (6461)
Job Trends (6278)
News (151384)
Policy (14197)
Tag
2027 BioCapital Standard (1)
2027 BioMidwest Digital (1)
2027 BioMidwest Standard (2)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Digital (1)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (2)
2027 Genetown Premier (1)
2027 Genetown Standard (2)
2027 Pharm Country Digital (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (6)
40 Under 40 (1)
Academia (467)
Accelerated approval (32)
ADA (11)
Adcomms (9)
Allergies (114)
Alliances (23378)
ALS (87)
Alzheimer's disease (573)
Antibody-drug conjugate (ADC) (234)
Approvals (6900)
Artificial intelligence (346)
ASCO (114)
Autoimmune disease (109)
Automation (26)
Bankruptcy (154)
Belgium (4)
Best Places to Work (4383)
BIO (24)
Biologics (37)
BIOSECURE Act (9)
Biosimilars (193)
BioSpace Insights (70)
Biotechnology (29)
Bispecific (9)
Bladder cancer (59)
Brain cancer (45)
Breast cancer (247)
Cancer (2041)
Cardiovascular disease (240)
Career advice (429)
Career pathing (15)
CAR-T (80)
CDC (11)
CDMO (91)
Celiac Disease (1)
Cell therapy (229)
Cervical cancer (23)
Clinical research (33250)
Collaboration (1116)
Commercialization (26)
Company closure (3)
Compensation (470)
Complete response letters (52)
COVID-19 (797)
CRISPR (61)
CRO (1)
C-suite (841)
Cystic fibrosis (68)
Data (3119)
Decentralized trials (2)
Denatured (19)
Depression (67)
Dermatology (38)
Diabetes (198)
Diagnostics (1524)
Digital health (18)
Diversity (2)
Diversity, equity & inclusion (14)
Drug discovery (210)
Drug pricing (125)
Drug shortages (16)
Duchenne muscular dystrophy (115)
Earnings (34828)
Editorial (25)
Employer branding (4)
Employer resources (48)
ESMO (122)
Events (40618)
Executive appointments (701)
Eye disease (2)
FDA (8185)
Fibrodysplasia Ossificans Progressiva (10)
Fragile X (4)
Friedreich's ataxia (3)
Frontotemporal dementia (6)
Funding (654)
Gene editing (96)
Generative AI (36)
Gene therapy (234)
GLP-1 (523)
Government (1456)
Grass and pollen (4)
Guidances (177)
Healthcare (3675)
Hematology (66)
HIV (22)
Huntington's disease (16)
Idiopathic pulmonary fibrosis (4)
IgA nephropathy (71)
Immunology and inflammation (101)
Immuno-oncology (46)
Indications (131)
Infectious disease (914)
Inflammatory bowel disease (96)
Inflation Reduction Act (7)
Influenza (31)
Intellectual property (162)
Interviews (59)
IPO (5959)
IRA (33)
Job creations (2062)
Job search strategy (377)
JPM (29)
Kidney cancer (18)
Kidney disease (54)
Labor market (48)
Layoffs (223)
Leadership (14)
Legal (3458)
Licensing (59)
Liver cancer (27)
Longevity (17)
Lung cancer (295)
Lung diease (5)
Lymphoma (180)
Machine learning (17)
Management (19)
Manufacturing (747)
Marketing (15)
MASH (99)
Medical affairs (3)
Medical device (1329)
Medtech (1355)
Mergers & acquisitions (10177)
Metabolic disorders (648)
mRNA (79)
Multiple sclerosis (74)
Multispecific (1)
NASH (15)
Netherlands (3)
Neurodegenerative disease (140)
Neuropsychiatric disorders (56)
Neuroscience (1226)
Neurotech (2)
NextGen: Class of 2026 (1588)
Non-profit (614)
Now hiring (29)
Obesity (333)
Opinion (157)
Ovarian cancer (80)
Pain (165)
Pancreatic cancer (83)
Parkinson's disease (128)
Partnered (15)
Patents (337)
Patient advocacy (1)
Patient recruitment (234)
Patient selection (28)
Peanut (16)
People (30734)
Peptides (12)
Pharmaceutical (34)
Pharmacy benefit managers (20)
Phase 1 (8591)
Phase 2 (14011)
Phase 3 (12736)
Pipeline (4887)
Policy (160)
Postmarket research (1407)
Preclinical (3458)
Press Release (25)
Prostate cancer (133)
Psychedelics (31)
Radioligand (1)
Radiopharmaceuticals (188)
Rare diseases (592)
Real estate (2673)
Recruiting (20)
Regenerative medicine (5)
Regulatory (11903)
Reports (20)
Research institute (586)
Resumes & cover letters (55)
Rett syndrome (17)
RNA editing (10)
RSV (28)
Schizophrenia (102)
Series A (131)
Series B (74)
Service/supplier (1)
Sickle cell disease (65)
Special edition (13)
Spinal muscular atrophy (86)
Sponsored (13)
Startups (1662)
State (2)
Stem cells (2)
Stomach cancer (8)
Substance use disorders (7)
Supply chain (77)
Switzerland (6)
Tariffs (72)
The Weekly (56)
Vaccines (310)
Venture capital (52)
Weight loss (188)
Wet AMD (3)
Women's health (68)
Worklife (5)
Date
Last 7 days (271)
Last 30 days (944)
Last 365 days (10640)
2026 (8984)
2025 (10754)
2024 (12504)
2023 (14281)
2022 (19595)
2021 (20092)
2020 (19043)
2019 (14887)
2018 (11713)
2017 (13897)
2016 (13129)
2015 (15486)
2014 (12443)
2013 (10610)
2012 (11414)
2011 (11963)
2010 (10932)
Location
Africa (328)
Alabama (25)
Alaska (1)
Arizona (105)
Arkansas (4)
Asia (21619)
Australia (2786)
California (4576)
Canada (2069)
China (926)
Colorado (200)
Connecticut (202)
Delaware (200)
Europe (42732)
Florida (876)
Georgia (88)
Hawaii (2)
Idaho (11)
Illinois (536)
India (102)
Indiana (371)
Iowa (3)
Japan (445)
Kansas (90)
Kentucky (23)
Louisiana (8)
Maine (2)
Maryland (563)
Massachusetts (3685)
Michigan (59)
Minnesota (240)
Mississippi (2)
Missouri (41)
Montana (9)
Nebraska (8)
Nevada (25)
New Hampshire (9)
New Jersey (2054)
New Mexico (7)
New York (1311)
North Carolina (851)
North Dakota (2)
Northern California (2210)
Ohio (112)
Oklahoma (6)
Oregon (17)
Pennsylvania (976)
Puerto Rico (22)
Rhode Island (19)
South America (510)
South Carolina (15)
Southern California (2034)
Tennessee (83)
Texas (638)
United States (18107)
Utah (74)
Vermont (1)
Virginia (248)
Washington D.C. (42)
Washington State (341)
West Virginia (1)
Wisconsin (75)
Wyoming (2)
282,252 Results for "eyepoint pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
EyePoint’s Phase 3 fail sends stock spiraling amid next-gen AMD race
EyePoint’s quest to reduce treatment burden for patients with age-related macular degeneration has hit a bump in the road, with a clinical miss driving the biotech’s stock down by 70%.
August 17, 2026
·
3 min read
·
Gabrielle Masson
Layoffs
EyePoint will halve workforce, end pivotal wet AMD trials early following second fail
EyePoint is initiating a strategic review after duravyu failed another Phase 3 trial in wet age-related macular degeneration. Amid significant layoffs and trial terminations, the company is shifting attention to the asset’s potential in diabetic macular edema.
October 19, 2026
·
2 min read
·
Angela Gabriel
Press Releases
EyePoint Announces Strategic Prioritization
October 19, 2026
·
12 min read
Press Releases
EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting
September 2, 2026
·
3 min read
Press Releases
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - September 16, 2026
September 16, 2026
·
2 min read
Press Releases
EyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYU™ in Wet AMD
October 19, 2026
·
13 min read
Press Releases
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - August 14, 2026
August 16, 2026
·
2 min read
Press Releases
EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments
August 5, 2026
·
13 min read
Press Releases
EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer
July 13, 2026
·
10 min read
Press Releases
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - July 16, 2026
July 16, 2026
·
2 min read
1 of 28,226
Next